48th week of 2012 patent applcation highlights part 40 |
Patent application number | Title | Published |
20120301414 | COMPOSITION IN THE FORM OF AN OIL-IN-WATER EMULSION AND USES THEREOF - Composition for topical application in the form of an oil-in-water emulsion containing an oily phase dispersed in an aqueous phase, and a hydrophilic polymer, the composition further containing (1) at least one elastomeric organopolysiloxane and (2) at least one lipophilic compound chosen from lipophilic amino acid compounds and lipophilic salicylic acid compounds. Uses thereof, including topical application to the skin, lips, hair, etc. Stabilization of certain emulsions using a lipophilic compound. | 2012-11-29 |
20120301415 | COMPOSITIONS HAVING ENHANCED COSMETIC PROPERTIES - A cosmetic composition and process which provides enhanced wear, comfort and feel, the composition containing: (a) at least one polypropylsilsesquioxane film forming resin; (b) at least one polymer chosen from a polyorganosiloxane copolymer and a silicone acrylate copolymer; (c) at least one solvent; and (d) optionally, at least one colorant. | 2012-11-29 |
20120301416 | Cosmetic Composition Containing A Polymer Blend - The present invention relates to a cosmetic composition containing a unique polymer blend, which includes: (a) a first polymeric film-former having a first glass transition temperature ranging from about −20° C. to about 0° C.; (b) a second polymeric film-former having a second glass transition temperature that is at least 50° C. higher than the first glass transition temperature; and (c) a third cross-linked polymeric film-former. The cosmetic composition of the present invention can be applied to human skin or keratinous fibers for forming a film thereon with exceptionally long wearability, reduced flaking and smudge properties, and good removability by warm water. | 2012-11-29 |
20120301417 | COMPOSITION FOR MAKING UP THE EYELASHES OR EYEBROWS, COMBINATION AND METHODS - A subject-matter of the present invention is a composition for making up keratinous fibres, comprising: —at least one compound or a mixture of compounds capable of conferring, on the said composition, a dmax threading nature of greater than or equal to 5 mm, —at least one noncyclic silicone oil exhibiting a viscosity at 25° C. of less than or equal to 300 cSt. Another subject-matter of the present invention is a method for making up keratinous fibres and also a packaging and applicational combination for a composition for making up keratinous fibres. | 2012-11-29 |
20120301418 | Hair Styling Cosmetic Composition - To provide a hair styling cosmetic composition which is excellent in hair styling property, hair restyling property and hair set retention property, even though being water-based and having a low viscosity, and is excellent in non-stickiness, smoothness, and light finish of the hair. A hair styling cosmetic composition comprising (a) a surfactant being solid at room temperature (25° C.) in an amount of from 1.5 to 12% by mass, (b) a polyalkylene glycol polymer being liquid at room temperature, and (c) a film-forming polymer, wherein the viscosity of the system is at most 10,000 mPa·s (at 25° C. with B-type viscometer). | 2012-11-29 |
20120301419 | Hair Styling Cosmetic Composition - To provide a hair styling cosmetic composition which is excellent in hair styling property, hair restyling property and hair set retention property, even though being water-based and having a low viscosity, and is excellent in non-stickiness, smoothness, and light finish of the hair. A hair styling cosmetic composition comprising (a) a surfactant being solid at room temperature (25° C.) in an amount of from 1.5 to 12% by mass, (b) one or more substances being solid at room temperature selected from among (b | 2012-11-29 |
20120301420 | HAIR TREATMENT COMPOSITIONS - The present invention relates to hair treatment compositions and methods. More particularly, the invention relates to hair treatment compositions comprising lipids and creatine. The hair treatment compositions of the present invention may be used to improve the tensile properties of hair, such as hair elasticity and strength. | 2012-11-29 |
20120301421 | Deodorizer Composition and Method - The present invention relates to deodorizing compositions. The invention also relates to deodorizing the interior of the ventilation systems. The invention also relates to deodorizing the interior of vehicle ventilation systems and distributes fresh scent when fan in system is turned on for either heat or air conditioning. The present invention also encompasses a process for deodorizing the interior of a vehicle. The invention also relates to processes for deodorizing the interior of the vehicle ventilation systems and distributes fresh scent when fan in system is turned on for either heat or air conditioning. | 2012-11-29 |
20120301422 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS AND OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM AGENTS AND TRANSPORTATION OF NUCLEIC ACID SUBSTANCES - The invention provides a method of enhancing the action of a pharmaceutical agent selected from the group consisting of the anti-infective agents, the group comprising of the antimicrobial agents, the anthelmintic agents and the anti-ectoparasitic agents, but excluding coal tar solution and H1-antagonist antihistamines, and from the group consisting of the CPNS agents selected from the group of compounds acting on the central or peripheral nervous system, but excluding coal tar solution and H1-antagonist antihistamines and also excluding anti-inflammatory, analgesic and antipyretic agents and also provides an enhanced method for the administration of a nucleic acid substance to the cells of an animal, a plant or a micro-organism. The method is characterised in that the agent or nucleic acid substance is formulated with an administration medium which comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which administration medium includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20:5ω3], decosahexaenoic acid [C22:6ω3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide. The formulations of such agents or substances form part of the invention | 2012-11-29 |
20120301423 | FUNCTIONALISED ANTIFOULING COMPOUNDS AND USE THEREOF - The present invention relates to derivatives of α,α-disubstituted amide compounds which comprise a substituted aryl at the α carbon such that the substituent provides a means for attachment or incorporation of the compound to or in a polymer. The provision of such a substituent on the aryl has surprisingly been found not only to permit attachment to or incorporation in a polymer but also retention of useful antifouling activity. In embodiments, the substituent is selected from hydroxyl, ethers, es ters, carboxyls, alkylsilyls and alkenyls. Experiments demonstrate that antifouling activity can be as good or better as the corresponding unsubstituted compound and that polymers functionalised so as to include or be formed from the substituted compound can be used to reduce settlement. | 2012-11-29 |
20120301424 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 2012-11-29 |
20120301425 | NOVEL ANTITUMORAL USE OF CABAZITAXEL - The invention relates to a compound of formula: | 2012-11-29 |
20120301426 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS - The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 2012-11-29 |
20120301427 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY - The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HW). | 2012-11-29 |
20120301428 | CLOSTRIDIUM GENE - The disclosure relates to the identification of an essential | 2012-11-29 |
20120301429 | DAC HYP COMPOSITIONS AND METHODS - The present disclosure relates to compositions of daclizumab suitable for subcutaneous administration and methods of manufacturing thereof. | 2012-11-29 |
20120301430 | THIOPHENE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - Compounds represented by formula I: | 2012-11-29 |
20120301431 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS - The present invention provides methods of treating (including preventing) a disease or condition associated with abnormal angiogenesis in a subject include administering a therapeutically effective amount of an AA targeting compound of the invention to the subject. The AA targeting compounds comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. | 2012-11-29 |
20120301432 | NOVEL BOSWELLIA LOW POLAR GUM RESIN EXTRACT AND ITS SYNERGISTIC COMPOSITIONS - The present disclosure describes | 2012-11-29 |
20120301433 | BACTERIOPHAGES EXPRESSING AMYLOID PEPTIDES AND USES THEREOF - The present invention generally relates to engineered bacteriophages which express amyloid peptides for the modulation (e.g. increase or decrease) of protein aggregates and amyloid formation. In some embodiments, the engineered bacteriophages express anti-amyloid peptides for inhibiting protein aggregation and amyloid formation, which can be useful in the treatment and prevention of and bacterial infections and biofilms. In some embodiments, the engineered bacteriophages express amyloid peptides for promoting amyloid formation, which are useful for increasing amyloid formation such as promoting bacterial biofilms. Other aspects relate to methods to inhibit bacteria biofilms, and methods for the treatment of amyloid related disorders, e.g., Alzheimer's disease using an anti-amyloid peptide engineered bacteriophages. Other aspects of the invention relate to engineered bacteriophages to express the amyloid peptides on the bacteriophage surface and/or secrete the amyloid peptides, e.g., anti-amyloid peptides and pro-amyloid peptides, and uses thereof for modulation protein aggregates and amyloid formation. | 2012-11-29 |
20120301434 | ANTIBACTERIAL POLYPEPTIDES AND USE THEREOF - The present invention discloses polypeptides with antibacterial properties and use said polypeptides and/or polynucleotides encoding said polypeptides in the preparation of medicament for the treatment of infectious diseases. The inventors also provide vectors encoding and adapted for expression of the polypeptides and polynucleotides of the invention. The vectors may be used in the preparation of a medicament for the treatment of bacterial infections. Further, the vector of the invention may be used to reduce the load of bacteria in food and/or feed. | 2012-11-29 |
20120301435 | PROBIOTIC BIFIDOBACTERIAL COMPOSITION IN ACCORDANCE WITH SECRETOR BLOOD GROUP STATUS - The present invention relates to a microbial or probiotic composition which is tailored based on the spectrum of bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals of non-secretor blood group phenotype. The present invention further relates to a method of tailoring a microbial or probiotic composition based on the bifidobacteria found in the intestine of at least one individual with secretor blood group phenotype but not commonly found in individuals non-secretor blood group phenotype. | 2012-11-29 |
20120301436 | POLYELECTROLYTE COMPLEX GELS AND SOFT TISSUE AUGMENTATION IMPLANTS COMPRISING THE SAME - The invention provides a polyelectrolyte complex gel comprising a chitosan and a γ-polyglutamic acid (γ-PGA) having a molecular weight from about 1 kDa to about 400 kDa or the salt thereof, wherein the chitosan and the γ-PGA are swollen with an aqueous solution. Also provided is a soft tissue augmentation implant, comprising a polyelectrolyte complex gel of the invention as a carrier or a filler and an optional additive. The polyelectrolyte complex gel and the soft tissue augmentation implant containing the same has long degradation time and better supportability so as to provide good maintenance for soft tissue. | 2012-11-29 |
20120301437 | Technologies, Methods, and Products of Small Molecule Directed Tissue and Organ Regeneration from Human Pluripotent Stem Cells - Pluripotent human embryonic stem cells (hESCs) hold great potential for restoring tissue and organ function, which has been hindered by inefficiency and instability of generating desired cell types through multi-lineage differentiation. This instant invention is based on the discovery that pluripotent hESCs maintained under defined culture conditions can be uniformly converted into a specific lineage by small molecule induction. Retinoic acid induces specification of neuroectoderm direct from the pluripotent state of hESCs and triggers progression to neuronal progenitors and neurons efficiently. Similarly, nicotinamide induces specification of cardiomesoderm direct from the pluripotent state of hESCs and triggers progression to cardiac precursors and cardiomyocytes efficiently. This technology provides a large supply of clinically-suitable human neuronal or cardiac therapeutic products for CNS or myocardium repair. This invention enables well-controlled efficient induction of pluripotent hESCs exclusively to a specific clinically-relevant lineage for tissue and organ engineering and regeneration, cell-based therapy, and drug discovery. | 2012-11-29 |
20120301438 | Reprogramming Blood Cells to Pluripotent and Multipotent Stem Cells - The present invention is based on the seminal discovery that cord blood (CB) and adult bone marrow (BM) CD34+ cells can be reprogrammed to early stem cells. The invention provides the reprogramming of CB and adult bone marrow (BM) CD34+ cells from subjects without any pre-treatment. Provided are methods for reprogramming blood cells of a subject. Also provided are methods of disease modeling and methods of generating subject-specific differentiated cells. In addition, the invention provides methods of identifying an agent that alters a function of subject-specific differentiated cells as well as isolated pluripotent or multipotent stem cells reprogrammed from blood cells. | 2012-11-29 |
20120301439 | INHIBITION OF CHOROIDAL NEOVASCULARIZATION - Methods of treatment of diseases that include or are characterized by inappropriate or pathological neovascularization are disclosed. These diseases include diseases of the eye, such as diabetic retinopathy, retinopathy of prematurity, and choroidal neovascularization which can occur in age-related macular degeneration (AMD). Disclosed methods include administering agents that cause directly or indirectly upregulation of the ABCA1 transporter protein in macrophages. These agents include, without limitation, LXR agonists. In some embodiments, inhibitors of CETP expression or activity can also be effective. Administration routes can include, without limitation, intraocular, periocular, or systemic administration. | 2012-11-29 |
20120301440 | METHODS AND MATERIALS FOR INCREASING POTENCY OF CELLS - Disclosed herein are methods and materials for producing a more developmentally potent cell from a less developmentally potent cell. Specifically exemplified herein are methods that comprise introducing an expressible dedifferentiating polynucleotide sequence into a less developmentally potent cell, wherein the transfected less developmentally potent cell becomes a more developmentally potent cell capable of differentiating to a less developmentally potent cell of its lineage of origin or a different lineage. | 2012-11-29 |
20120301441 | DEXTRAN-HYALURONIC ACID BASED HYDROGELS - The invention provides a copolymer of hyaluronic acid (HA) grafted with a dextran-tyramine (Dex-TA) conjugate. | 2012-11-29 |
20120301442 | TREATMENT OF BONE FRACTURE - The use of mesenchymal stem cells cultured in the presence of HS-2 for the treatment of bone fracture. Repair of bone fracture using such cells is enhanced compared with the treatment of bone fracture using mesenchymal cells cultured without HS-2. These mesenchymal stem cells may be formulated in a pharmaceutical composition and injected directly into tissues surrounding the fracture or used in a biocompatible implant or prosthesis. | 2012-11-29 |
20120301443 | METHODS FOR DEVELOPING ENDOTHELIAL CELLS FROM PLURIPOTENT CELLS AND ENDOTHELIAL CELLS DERIVED - Disclosed herein is a method for developing human endothelial cells (ECs) from human embryonic stem cells (ESCs). The method is based on inhibition of TGF signaling following mesoderm induction and during vascular differentiation of hESC-derived cells. Also disclosed herein is a substantially pure and stable population of ECs that maintains a high degree of proliferation and phenotypic homogeneity for extended culture periods. Related pharmaceutical compositions and therapeutic methods are also disclosed. A reporter hESC line useful for tracking the development of ECs is also provided. | 2012-11-29 |
20120301444 | Amnion-derived cell compositions, methods of making and uses thereof - The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies. | 2012-11-29 |
20120301445 | TOOLS FOR ISOLATING AND FOLLOWING CARDIOVASCULAR PROGENITOR CELLS - The present invention provides new methods and tools for isolating pluripotent cardiovascular progenitors (MCPs), by transiently detecting the cell-surface expression of genes upregulated by Mesp1. Cells obtained by the method and there uses in research and clinical settings are also part of the invention. Using genome wide transcriptional analysis, the inventors found upstream and downstream members of the Mesp1 signaling pathway, which form potential new targets for both therapy and for the identification of MCPs and differentiation of MCPs into cardiovascular cells. This invention provides novel and important insights into the molecular mechanisms of cardiovascular specification and provides potential novel methods for dramatically increasing the number of cardiovascular cells for cellular therapy in humans. | 2012-11-29 |
20120301446 | COMPOSITIONS AND METHODS FOR RE-PROGRAMMING CELLS WITHOUT GENETIC MODIFICATION FOR TREATMENT OF NEUROLOGICAL DISORDERS - The present inventions are directed to compositions and methods regarding the reprogramming of other cells (such as glial cells) into neurons without introducing exogenous genes to the samples. In particular, the present inventions are directed to transducible materials that are capable of transducing into the biological samples but are not genes or causing genetic modifications. The present inventions also are directed to methods of reprogramming the path of biological samples or treating diseases using the transducible compositions thereof. | 2012-11-29 |
20120301447 | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION - A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways. Thus, EGFRt may be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential. | 2012-11-29 |
20120301448 | TH1-ASSOCIATED MICRORNAS AND THEIR USE FOR TUMOR IMMUNOTHERAPY - Described herein is the identification of miRNAs (miRs) that are up-regulated in Th1 cells compared to Th2 cells (referred to herein as Th1-associated miRs). In particular, the miR-17-92 gene cluster was found to exhibit significantly greater expression in Th1 cells. Over-expression of miR-17-92 in T cells promotes the Th1 phenotype. Thus, the use of Th1-associated miRs for cancer immunotherapy is described. Provided herein are isolated T cells containing a heterologous nucleic acid molecule encoding a Th1-associated miR, such as the miR17-92 gene cluster, or a portion thereof. Further provided is a method of treating cancer in a subject by administering to the subject an isolated T cell as disclosed herein. Also provided is a method of treating a subject with cancer by transfecting isolated T cells obtained from the subject with a heterologous nucleic acid molecule encoding a Th1-associated miR and administering the transfected T cells to the subject. | 2012-11-29 |
20120301449 | RNA INTERFERENCE TARGET FOR TREATING AIDS - The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS. | 2012-11-29 |
20120301450 | MIXTURE, DISSOLVING SOLUTION AND PHARMACEUTICAL AGENT EACH COMPRISING THERMOPHILIC MICROORGANISM - To provide a mixture, a dissolving solution and a pharmaceutical agent, which contain a thermophilic microorganism to make it possible to regulate a mucous membrane immune system gene cluster and metabolism-related gene clusters of the intestines and the liver. Each of them is prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less. By being administered to the animal, it regulates at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines, and a metabolism-related gene cluster in the liver of the animal. The microorganism includes at least one species of the genus | 2012-11-29 |
20120301451 | NON-FERMENTED COMPOSITIONS COMPRISING A CEREAL BASED FRACTION AND A PROBIOTIC AND USES THEREOF - The present invention relates to a non-fermented composition having the ability to increase the formation of butyric acid in the colon and comprising at least one cereal based fraction and at least one isolated probiotic strain of | 2012-11-29 |
20120301452 | PROBIOTIC MICROORGANISMS AS ACTIVE AGENTS FOR ENHANCING THE RADIANCE OF THE SKIN'S COMPLEXION - The invention relates to the use of at least one probiotic microorganism as an active agent for preventing and/or treating impaired radiance of the skin's complexion. | 2012-11-29 |
20120301453 | INHIBITING INTEGRIN RECEPTOR BINDING WITH NON-NATIVE MONOMERIC DISINTEGRIN OR MONOMERIC DISINTEGRIN DOMAINS - This invention relates to methods of inhibiting binding between a cell expressing integrin receptors specific for one or more integrins selected from the group consisting of αIIbβ3, αvβ3, αvβ5, or α5β1, said method comprising contacting the cell with a monomeric disintegrin or monomeric disintegrin domain which comprises a C-terminal sequence non-native to the disintegrin or disintegrin domain, said C-terminal sequence encoding a functional integrin-binding loop. | 2012-11-29 |
20120301454 | Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy - Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions. | 2012-11-29 |
20120301455 | BOTULINUM TOXIN COMPOSITIONS - A high potency botulinum toxin pharmaceutical composition comprising two excipients (such as albumin and sodium chloride) in a weight to weight ratio of between about 1 and about 100. | 2012-11-29 |
20120301456 | MEGANUCLEASE REAGENTS OF USES THEREOF FOR TREATING GENETIC DISEASES CAUSED BY FRAME SHIFT/NON SENSE MUTATIONS - The present invention relates to a method to treat a genetic disease in an individual caused by at least one frame shift or at least one non sense mutation in the human dystrophin gene comprising at least the step of bringing into contact at least one meganuclease enzyme, which recognizes and cuts a target site in the human dystrophin gene, with the genome of said individual under conditions wherein said at least one meganuclease recognizes and cleaves its target site in the human dystrophin gene. Said method applies also to a set of meganuclease enzymes, which each recognizes and cuts a different target site. The present invention also relates to a kit comprising, at least one meganuclease enzyme as defined above and medicament comprising said meganuclease. | 2012-11-29 |
20120301457 | LIPID COFACTORS FOR FACILITATING PROPOGATION OF PRPsc - The present invention embraces methods and kits for facilitating the propogation of PrP | 2012-11-29 |
20120301458 | CYCLOPROPYL MODULATORS OF P2Y12 RECEPTOR - The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof | 2012-11-29 |
20120301459 | COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) - The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine. | 2012-11-29 |
20120301460 | SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY - The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed. | 2012-11-29 |
20120301461 | 1D05 PCSK9 ANTAGONISTS - Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure. | 2012-11-29 |
20120301462 | Compounds - Binding members, e.g. human antibody molecules, which bind interleukin-6 (IL-6) and neutralise its biological effects. Use of binding members for IL-6 in medical treatment e.g. for treating inflammatory diseases and tumours associated with IL-6. | 2012-11-29 |
20120301463 | Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products - The present disclosure relates to methods for the modulation of autophagy and the treatment of autophagy-related diseases, including cancer, neurodegenerative diseases and pancreatitis. | 2012-11-29 |
20120301464 | JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES - Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor. | 2012-11-29 |
20120301465 | COMPOSITIONS AND METHODS TO IMMUNIZE AGAINST HEPATITIS C VIRUS - Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C. | 2012-11-29 |
20120301466 | CHEMICALLY PROGRAMMABLE IMMUNITY - Methods and compositions for immediately immunizing an individual against any molecule or compound. The present invention comprises an immunity linker with at least two sites; (1) at least one first binding site that binds to an immune response component in an individual that has been pre-immunized with a universal immunogen, and (2) at least one second binding site that binds specifically to a desired compound or molecule, the target. | 2012-11-29 |
20120301467 | FAS BINDING ANTIBODIES - The disclosed invention relates to monoclonal antibodies (MAbs) which recognize human fatty acid synthase (hFAS) and are distinct from previously known anti-hFAS antibodies. Compositions, devices and kits comprising the MAbs are provided along with methods of using the MAbs in a variety of applications. | 2012-11-29 |
20120301468 | ANTI-MN ANTIBODIES AND METHODS OF USING SAME - The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods of using such antibodies in treating and diagnosing an MN-related disorder. | 2012-11-29 |
20120301469 | AMINO ACID SEQUENCES DIRECTED AGAINST HUMAN RESPIRATORY SYNCYTIAL VIRUS (HRSV) AND POLYPEPTIDES COMPRISING THE SAME FOR THE PREVENTION AND/OR TREATMENT OF RESPIRATORY TRACT INFECTIONS - Amino acid sequences are provided that are directed against/and or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes. | 2012-11-29 |
20120301470 | USE OF TYROSINE KINASE INHIBITORS FOR TREATMENT OF CUSHING'S DISEASE AND HYPERCORTISOLISM - The invention relates to methods and kits for the treatment of, prevention of, and lowering the chances of developing Cushing's Disease and/or hypercortisolism by the administration of a tyrosine kinase inhibitor, such as gefitinib. | 2012-11-29 |
20120301471 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER - According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence. | 2012-11-29 |
20120301472 | REAGENTS AND TREATMENT METHODS FOR AUTOIMMUNE DISEASES - The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22). | 2012-11-29 |
20120301473 | ANTIBODIES SELECTIVE FOR PATHOLOGICAL TAU DIMERS AND PREFIBRILLAR PATHOLOGICAL TAU OLIGOMERS AND THEIR USES IN TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES - Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses of these antibodies, immunogenic peptides and epitopes in preparation of pharmaceutical compositions for the treatment of tauopathies, and uses of these antibodies, immunogenic peptides, epitopes and pharmaceutical compositions in the treatment of tauopathies are described. Also described are uses of these antibodies, immunogenic peptides, epitopes in diagnosis and monitoring of tauopathies. | 2012-11-29 |
20120301474 | COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST DRUG RESISTANT ACINETOBACTER BAUMANNII - The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against | 2012-11-29 |
20120301475 | NOVEL HEPARANASE SPLICE VARIANT - The present invention, in at least some aspects, is of splice variants of heparanase, as well as diagnostic kits and methods of use, and therapeutic agents and methods of use based thereon, and antibodies specifically binding thereof. | 2012-11-29 |
20120301476 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING CANCER - According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity to a partial polypeptide of CAPRIN-1, which is represented by any of even-numbered sequences of SEQ ID NOS: 2 to 30, wherein the polypeptide has the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence. | 2012-11-29 |
20120301477 | USE OF CCR9, CCL25/TECK, AND INTEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE - The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin α4 gene. Also disclosed are methods for treating subjects so identified. | 2012-11-29 |
20120301478 | Pharmaceutical for Preventing or Treating Disorders Accompanied by Ocular Angiogenesis and/or Elevated Ocular Vascular Permeability - A pharmaceutical for preventing or treating a disorder accompanied by ocular angiogenesis and/or increased ocular vascular permeability, constituted by a combination of an anti-VEGF agent, and a hydantoin derivative represented by a general formula (I): (in the formula, X represents a halogen atom or a hydrogen atom, and R | 2012-11-29 |
20120301479 | HENDRA VIRUS RECOMBINANT COMPOSITIONS AND USES THEREOF - The present invention provides vectors that contain and express in vivo or in vitro one or more Hendra virus polypeptides or antigens that elicit an immune response in animal or human against Hendra virus and Nipah virus, compositions comprising said vectors and/or Hendra virus polypeptides, methods of vaccination against Hendra virus and Nipah virus, and kits for use with such methods and compositions. | 2012-11-29 |
20120301480 | H. PYLORI LIPOPOLYSACCHARIDE OUTER CORE EPITOPE - Dextrans produced by lactic acid bacteria | 2012-11-29 |
20120301481 | TARGETING POLY-GAMMA-GLUTAMIC ACID TO TREAT STAPHYLOCOCCUS EPIDERMIDIS AND RELATED INFECTIONS - Immunogenic compositions and methods for eliciting an immune response against | 2012-11-29 |
20120301482 | METHODS AND COMPOSITIONS FOR TREATMENT OF LUNG INJURY - The present invention provides a method to treat a condition related to injury of lung epithelial cells in a subject by administering a compound that binds FgfR2b, for example to promote proliferation of lung epithelial stem cells, as well as such compounds in pharmaceutical formulations. The invention also provides for methods to treat a condition related to injury of lung epithelial cells by isolating cells expressing FgfR2b, multiplying the cells and introducing the multiplied cells for repair of lung injury. Related methods for detecting lung injury by detecting the level of expression of FgfR2b well as for treating a condition related to proliferation of lung epithelial cells by administering a compound that binds to FgfR2b, to block receptor signaling are also provided. | 2012-11-29 |
20120301483 | COMPLEMENT PATHWAY INHIBITORS BINDING TO C5 AND C5A WITHOUT PREVENTING THE FORMATION OF C - The invention relates to inhibitors that bind to C5 and C5a, but which do not prevent the activation of C5 and do not prevent formation of or inhibit the activity of C5b. One example of such an inhibitor molecule is the monoclonal antibody designated MAb137-26, which binds to a shared epitope of human C5 and C5a. These inhibitors may be used to inhibit the activity of C5a in treating diseases and conditions mediated by excessive or uncontrolled production of C5a. The inhibitor molecules are also useful for diagnostic detection of the presence/absence or amount of C5 or C5a. | 2012-11-29 |
20120301484 | REGULATORY T CELL MEDIATOR PROTEINS AND USES THEREOF - The present invention relates to novel regulatory T cell proteins. One protein, designated PD-L3, resembles members of the PD-L1 family, and co-stimulates αCD3 proliferation of T cells in vitro. A second, TNF-like, protein has also been identified as being upregulated upon αCD3/αGITR stimulation. This protein has been designated T | 2012-11-29 |
20120301485 | Juvenile Hemochromatosis Gene (HFE2A) Cleavage Products and Uses Thereof - Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided. | 2012-11-29 |
20120301486 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful. | 2012-11-29 |
20120301487 | METHOD FOR IN-VIVO BINDING OF CHROMATIN FRAGMENTS - A process for substantially reducing levels of circulating chromatin fragments (CCFs) from a medium using binding agents such as antibodies or antibodies complexed with haemocompatible natural polymer substrates like as alginates, chitosan and pullulan to form complexed antibody-substrate nano-particulates (CNP) to bind and/or inactivate CCFs is disclosed. The amount of antibody bound to the polymer varies from 30% to 100% of activated sites in the polymer. Elevated levels of CCFs can be substantially reduced following administration of tissue damaging agents that generate apoptotic chromatin fragments by the concomitant administration of CNPs or concomitant administration of H4 antibody alone. A method of treatment is disclosed wherein therapeutic dose of CNPs, or H4 antibody alone, are administered systematically, or orally, in a delivery system to curb pathological conditions that are associated with increased burden of circulating chromatin fragments. | 2012-11-29 |
20120301488 | ANTI-CD40 ANTIBODIES AND METHODS OF USE - The present invention provides high affinity anti-CD40 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of cancer and other diseases. | 2012-11-29 |
20120301489 | Jagged-Binding Agents and Uses Thereof - Antibodies that specifically bind to an extracellular domain of human Jagged 1 or human Jagged2 and modulate Jagged activity, and methods of using said antibodies to inhibit tumor growth are disclosed. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an anti-Jagged antibody to a patient having a tumor or cancer. | 2012-11-29 |
20120301490 | IMMUNOCONJUGATES, COMPOSITIONS FOR MAKING THEM, AND METHODS OF MAKING AND USE - An immunoconjugate in which a phosphate-prodrugged DNA minor groove binding agent of formula (I), where X is a nucleophilically displaceable leaving group, is conjugated to an antibody or an antigen binding fragment of an antibody, and compounds that can be used for making such immunoconjugates, and uses of such immunoconjugates. | 2012-11-29 |
20120301491 | Use of Modified Extracellular Matrix Proteins in Diagnosis and Treatment of Atherosclerosis - The present invention relates to the use of fibronectin, tenascin, collagens type I, III, VI and/or VIII modified by aldehyde or by glycosylation in ELISA for detection of antibodies in plasma and serum to diagnose atherosclerosis as well as the use of induction of tolerance and active as well as passive immunization against glycosylated or aldehydemodified fibronectin, tenascin, collagen type I, III, VI and/or VIII for prevention and treatment of atherosclerosis. | 2012-11-29 |
20120301492 | COMPOSITIONS AND METHODS FOR WT1 SPECIFIC IMMUNOTHERAPY - Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases. | 2012-11-29 |
20120301493 | APPLICATIONS OF THE PROTEIN MUNS AND THE DERIVATES THEREOF - The invention is based on the identification of the minimum region of the avian | 2012-11-29 |
20120301494 | PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E VIRUS AS AN ORAL DELIVERY VECTOR - This invention provides a peptide/nucleic acid composition for oral/mucosal, dual-modal activation of immune protection systems. | 2012-11-29 |
20120301495 | ANTIGEN PEPTIDE AND USE THEREOF - In order to provide an effective vaccine against infection with Propionibacterium acnes, the present invention provides a peptide which is a peptide consisting of a specific amino acid sequence or a peptide consisting of an amino acid sequence derived from the specific amino acid sequence by deletion, substitution, insertion, or addition of one or more amino acids, the peptide suppressing, by immune response, inflammation caused by infection with Propionibacterium acnes. | 2012-11-29 |
20120301496 | NOVEL IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCCAL DISEASE - The present invention relates to | 2012-11-29 |
20120301497 | Plasmodium vivax Hybrid Circumsporozoite Protein and Vaccine - Described in this application is a synthetic | 2012-11-29 |
20120301498 | CONTROLLED RELEASE OF IMMUNOSUPPRESSANTS FROM SYNTHETIC NANOCARRIERS - Disclosed are synthetic nanocarrier compositions that provide controlled release of immunosuppressants as well as related methods. The synthetic nanocarrier compositions may also include antigen in some embodiments. | 2012-11-29 |
20120301499 | Packaging of Immunostimulatory Substances into Virus-Like Particles: Method of Preparation and Use - The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases. | 2012-11-29 |
20120301500 | ANTI-SEPSIS CONJUGATE VACCINE - The present invention provides an immunogenic conjugate comprising biologically deacylated gram-negative bacterial moieties linked to | 2012-11-29 |
20120301501 | METHOD FOR SELECTING AND PRODUCING VACCINE COMPONENTS AND VACCINES BASED THEREON - The invention relates to the field of biology, more specifically to the field of immunology and microbiology. The invention further relates to the field of vaccines against microbial infections and especially bacterial vaccines, in particular to pneumococcal vaccines. More in particular, the invention relates to means and methods to identify, select and isolate a vaccine component for passive and/or active immunisation against a microorganism that can be killed by opsonophagocytic cells. The invention relates to a method to identify an opsonophagocytosis inducing antigen as a vaccine component for immunisation against a microorganism. The invention describes three pneumococcal proteins SlrA, IgA1 proteinase, and PsaA, and their use as a vaccine component with or without PpmA. The invention also discloses the use of antibodies against said proteins for passive immunization and diagnosis. | 2012-11-29 |
20120301502 | 15-VALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE COMPOSITION - The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of | 2012-11-29 |
20120301503 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2012-11-29 |
20120301504 | Influenza Virus Recombinant Proteins - The present invention includes influenza Hemagglutinin protein fragments that fold properly when expressed in bacteria. | 2012-11-29 |
20120301505 | Immunostimulating Agent and Method for Production Thereof - The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunomodulating effect of the immunomodulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage like strain RAW264 or J774.1, a murine splenocyte, a murine peritoneal macrophage and a murine dendrocyte. A composition containing the immunomodulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition. | 2012-11-29 |
20120301506 | Oncolytic Virus as an Inducer for Innate Antitumor Immunity - The present invention is directed to the administration of FusOn-H2, an HSV derived oncolytic virus, to treat tumor cells that are resistant to the lytic effect of the virus. Administration of FusOn-H2 induces the patient's innate immune responses to tumor cells via neutrophils, which are able to destroy tumors efficiently when they migrate to the tumor mass. With the induced innate antitumor immunity, FusOn-H2 is effective at eradicating tumors even when it is used at very low doses. | 2012-11-29 |
20120301507 | METHOD OF TISSUE REPAIR - The present invention relates to methods of repairing tissue. More specifically, the present invention relates to methods of using cells and an implantable support for the repair of tissue defects, where the implantable support and cells are implanted into the tissue defect less than 2 hours after the cells are applied to the support. | 2012-11-29 |
20120301508 | Compositions for Induction of Osteogenesis around an Implant - The invention relates to a composition for induction of osteogenesis around an implant comprises a chitosan having a degree of deacetylation at the range of 70%˜90% and a collagen, wherein the implant is a titanium implant. The composition of the present invention is able to effectively induce osteogenesis in organisms and can be used to promote bone formation and osseointegration of an implant. | 2012-11-29 |
20120301509 | BOLDLINE COMPOUNDS FOR PROMOTING BONE GROWTH - The present invention provides a method of promoting bone growth in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I. The present invention also provides methods for the treatment of renal disease and cancer. | 2012-11-29 |
20120301510 | TOLEROGENIC SYNTHETIC NANOCARRIERS COUPLED TO CD1D-RESTRICTED ANTIGENS AND METHODS OF USE - Disclosed are synthetic nanocarrier compositions, and related methods, comprising CD1d-restricted antigens and immunosuppressants that provide tolerogenic immune responses. | 2012-11-29 |
20120301511 | TOPICAL FORMULATION COMPRISING A CORTICOSTEROID AS ACTIVE INGREDIENT - Formulation in the form of aqueous suspension of drug particles of a corticosteroid for topical administration are effective for the prophylaxis and/or treatment of a dermatological disease such as atopic dermatitis, acne and psoriasis. | 2012-11-29 |
20120301512 | Tetrary Gene Delivery System for Gene Therapy and Methods of Its Use - Delivery systems and their methods of formation are generally provided. The delivery system can protect a delivery molecule (e.g., DNA/RNA) and deliver it into a cell via serum. In one embodiment, the method can include binding a delivery molecule with polyethylenimine such that an end of the delivery molecule is exposed; capping the end of the delivery molecule with a first biocompatible polymer to form a core; and encapsulating the core with a second biocompatible polymer. The resulting delivery system can include a delivery molecule bonded with polyethylenimine such that an end of the delivery molecule is exposed; a first biocompatible polymer electrostatically bonded to the end of the delivery molecule to form a core; and a second biocompatible polymer encapsulating the core. | 2012-11-29 |
20120301513 | COMPOSITION COMPRISING SOLANUM GLAUCOPHYLLUM FOR PREVENTING AND/OR TREATING HYPOCALCAEMIA AND FOR STABILIZING BLOOD CALCIUM LEVELS - The present invention provides a pharmaceutical and/or veterinary composition comprising a retard release formulation of a | 2012-11-29 |